{"id":"W3036940367","doi":"10.1182/bloodadvances.2019001367","title":"KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Leukemia and Lymphoma Society","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Internal medicine; Oncology; Hodgkin lymphoma; Lymphoma; Cancer research; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002224933,0.000406249,0.001111528,0.0004957764,0.0005562612,0.0007232091,0.0004333296,0.0007197552,0.001428263],"category_scores_gemma":[0.002177346,0.0002128553,0.0007240939,0.0004829339,0.0002373767,0.0008329573,0.0005237368,0.001258951,0.0004358844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007277369,"about_ca_system_score_gemma":0.0003420138,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001066777,"about_ca_topic_score_gemma":0.001293703,"domain_scores_codex":[0.9994428,0.0001901101,0.00005497519,0.00009892391,0.00007716423,0.0001360515],"domain_scores_gemma":[0.9984659,0.0003034152,0.0004853398,0.0001302958,0.0002224576,0.0003925508],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1632973,0.005633086,0.6516883,0.0005964316,0.002146299,0.003280463,0.000622532,0.002627721,0.02439676,0.0002300995,0.005068228,0.1404128],"study_design_scores_gemma":[0.004843525,0.05904946,0.9221314,0.00009067671,0.001641858,0.001704222,0.0001686362,0.001838604,0.003892768,0.0001964601,0.004378887,0.00006350196],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957397,0.00205104,0.0002064622,0.00007404436,0.00001915837,0.00009200376,0.0008570531,0.00002391621,0.0009367243],"genre_scores_gemma":[0.9972235,0.0003096042,0.000103304,0.0001077805,0.00002434742,0.00005705834,0.00174783,0.000004210865,0.0004223534],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002224933,"threshold_uncertainty_score":0.01176673,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01037364622421822,"score_gpt":0.2406844353598989,"score_spread":0.2303107891356807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}